PCI Biotech Holding ASA (FRA:4QG) Long-Term Capital Lease Obligation : €0.02 Mil (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Long-Term Capital Lease Obligation?

PCI Biotech Holding ASA's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.02 Mil.

PCI Biotech Holding ASA's quarterly Long-Term Capital Lease Obligation declined from Dec. 2022 (€0.03 Mil) to Mar. 2023 (€0.03 Mil) and declined from Mar. 2023 (€0.03 Mil) to Jun. 2023 (€0.02 Mil).

PCI Biotech Holding ASA's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€0.13 Mil) to Dec. 2022 (€0.03 Mil) and declined from Dec. 2022 (€0.03 Mil) to Dec. 2023 (€0.00 Mil).

PCI Biotech Holding ASA Long-Term Capital Lease Obligation Historical Data

The historical data trend for PCI Biotech Holding ASA's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Long-Term Capital Lease Obligation Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.05

0.13

0.03

PCI Biotech Holding ASA Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.08	0.03	0.03	0.02	-

PCI Biotech Holding ASA (FRA:4QG) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

PCI Biotech Holding ASA Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA (FRA:4QG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (FRA:4QG) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

PCIB:Norway

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.

PCI Biotech Holding ASA (FRA:4QG) Headlines

No Headlines